Payment overview · 2025
General Payments
$383.02
22 reported records · 8 companies
Healthcare provider profile · identity verified
Sara Rhoades, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · WILLIAMSTON, NC · NPI 1730554072
Verified facts
What the public records show
CMS Open Payments records show Sara Rhoades, FNP received $383.02 in general payments during 2025 across 22 reported records.
AstraZeneca Pharmaceuticals LP accounted for 28.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $108.94 | 28.4% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $48.36 | 12.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $46.55 | 12.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $46.54 | 12.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $44.11 | 11.5% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.63 | 9.8% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $32.53 | 8.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.36 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $383.02 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $93.09 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $48.36 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $46.54 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $46.54 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $44.11 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $44.11 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $37.63 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $32.53 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.03 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.03 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.85 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 121 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 160 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 44 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
43 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
160 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
121 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 671 | 226 |
| Amlodipine Besylate | Amlodipine Besylate | 588 | 186 |
| Losartan Potassium | Losartan Potassium | 424 | 131 |
| Hydrochlorothiazide | Hydrochlorothiazide | 420 | 129 |
| Lisinopril | Lisinopril | 379 | 119 |
| Omeprazole | Omeprazole | 340 | 107 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 338 | 109 |
| Levothyroxine Sodium | Levothyroxine Sodium | 313 | 79 |
| Gabapentin | Gabapentin | 250 | 79 |
| Metformin Hcl Er | Metformin Hcl | 227 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 200 | 81 |
| Pravastatin Sodium | Pravastatin Sodium | 197 | 61 |
| Carvedilol | Carvedilol | 186 | 61 |
| Simvastatin | Simvastatin | 175 | 58 |
| Fluticasone Propionate | Fluticasone Propionate | 168 | 60 |
| Allopurinol | Allopurinol | 160 | 59 |
| Ozempic | Semaglutide | 160 | 27 |
| Atenolol | Atenolol | 142 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 141 | 53 |
| Tramadol Hcl | Tramadol Hcl | 135 | 29 |
| Potassium Chloride | Potassium Chloride | 128 | 52 |
| Sertraline Hcl | Sertraline Hcl | 128 | 45 |
| Eliquis | Apixaban | 121 | 27 |
| Prednisone | Prednisone | 115 | 84 |
| Furosemide | Furosemide | 109 | 39 |
| Glipizide | Glipizide | 109 | 30 |
| Metformin Hcl | Metformin Hcl | 108 | 35 |
| Trazodone Hcl | Trazodone Hcl | 99 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 97 | 50 |
| Montelukast Sodium | Montelukast Sodium | 87 | 25 |
| Ezetimibe | Ezetimibe | 86 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 30 |
| Jardiance | Empagliflozin | 84 | 15 |
| Glipizide Er | Glipizide | 82 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 82 | 28 |
| Alprazolam | Alprazolam | 80 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 74 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 73 | 32 |
| Alendronate Sodium | Alendronate Sodium | 72 | 24 |
| Famotidine | Famotidine | 72 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 71 | 27 |
| Buspirone Hcl | Buspirone Hcl | 65 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 64 | 61 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 61 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 59 | 30 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 56 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 31 |
| Mirtazapine | Mirtazapine | 55 | 17 |
| Meloxicam | Meloxicam | 54 | 22 |
| Pregabalin | Pregabalin | 52 | 16 |
| Xarelto | Rivaroxaban | 52 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 17 |
| Valsartan | Valsartan | 48 | 12 |
| Nifedipine Er | Nifedipine | 47 | 15 |
| Chlorthalidone | Chlorthalidone | 45 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 42 |
| Repatha Sureclick | Evolocumab | 44 | suppressed |
| Rybelsus | Semaglutide | 44 | 11 |
| Linzess | Linaclotide | 43 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | 12 |
| Nystatin | Nystatin | 42 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 42 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Trulicity | Dulaglutide | 37 | 11 |
| Fluconazole | Fluconazole | 36 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 35 | 11 |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 14 |
| Myrbetriq | Mirabegron | 34 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 11 |
| Lorazepam | Lorazepam | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 31 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 32 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Bumetanide | Bumetanide | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Klor-Con M20 | Potassium Chloride | 30 | 12 |
| Azithromycin | Azithromycin | 29 | 28 |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 11 |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 24 |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 15 |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Prolia | Denosumab | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $383.02 · 22 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Cologuard Collection Kit, ELIQUIS, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, SHINGRIX, VRAYLAR, Wegovy, YUPELRI | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error